Health Canada approves Descovy for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.- Gilead Sciences

Gilead Sciences’ Canada has filed a supplemental marketing application with Health Canada seeking approval for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection among individuals who are HIV-negative and at risk for HIV.

Descovy was approved in Canada in 2016 for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg (in combination with other antiretrovirals).